GMAB · Genmab A/S
$29.17
-0.69% last session
End-of-day data · updated 2026-07-25
Market cap
$18B
Enterprise value
$22B
Trailing P/E
21.9
Forward P/E
15.4
Dividend yield
—
Beta
0.69
Avg volume
2M
Employees
3K
2D change
-1.03%
5D change
3.44%
10D change
-0.72%
30D change
10.44%
60D change
7.36%
MTD change
4.45%
YTD change
-6.27%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GMAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-22
Latest call per bank · past 12 months
Wells Fargo
Overweight$40.00
+37.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-22 | TD Cowen | Upgrade | Hold → Buy | $32.00 → $43.00 |
| 2026-07-02 | HC Wainwright & Co. | Maintains | Buy | $38.00 → $40.00 |
| 2026-06-23 | HC Wainwright & Co. | Reiterates | Buy | $38.00 |
| 2026-04-30 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $38.00 |
| 2026-03-27 | Wolfe Research | Initiates | Outperform | $0.00 → $32.00 |
| 2026-03-02 | Wells Fargo | Initiates | Overweight | $0.00 → $40.00 |
| 2026-02-23 | Guggenheim | Maintains | Buy | $45.00 → $40.00 |
| 2026-02-18 | HC Wainwright & Co. | Maintains | Buy | $39.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.1% above the 50-day MA ($26.81).
- Price vs 200-day MA: Trading 0.6% below the 200-day MA ($29.15).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($21.08) and high ($35.34).
GMAB Price Chart
Loading chart for GMAB…
Fundamentals
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.